Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection

Vaccine

Volumn 34, Issue 17, 2016, Pages 1993-1999

  Cardin, Rhonda D ^a   Bravo, Fernando J ^a   Pullum, Derek A ^a   Orlinger, Klaus ^b   Watson, Elizabeth M ^b   Aspoeck, Andreas ^b   Fuhrmann, Gerhard ^b   Guirakhoo, Farshad ^b   Monath, Thomas ^b   Bernstein, David I ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b HOOKIPA BIOTECH AG   (Austria)

Author keywords

Congenital CMV; Cytomegalovirus; Glycoprotein B; GPCMV; Guinea pig; pp65; Vaccine

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN GB; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS GB VACCINE; CYTOMEGALOVIRUS PP65 VACCINE; CYTOMEGALOVIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; GLYCOPROTEIN B, SIMPLEXVIRUS; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREEDING; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MORTALITY; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; SURVIVAL; VACCINATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; BLOOD; CYTOMEGALOVIRUS INFECTIONS; GUINEA PIG; HEK293 CELL LINE; IMMUNOLOGY; NEWBORN; PHYSIOLOGY; ROSEOLOVIRUS;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; GUINEA PIGS; HEK293 CELLS; HUMANS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PHOSPHOPROTEINS; PREGNANCY; ROSEOLOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 84964345597     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.005     Document Type: Article

References (34)

1. Nelson C.T., Demmler G.J. Cytomegalovirus infection in the pregnant mother, fetus, and newborn infant. Clin Perinatol 1997, 24:151-160.
2. Pass R.F., Stagno S., Myers G.J., Alford C.A. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics 1980, 66:758-762.
3. Fowler K.B., McCollister F.P., Dahle A.J., Boppana S., Britt W.J., Pass R.F. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997, 130:624-630.
4. Ivarsson S.A., Lernmark B., Svanberg L. Ten-year clinical, developmental, and intellectual follow-up of children with congenital cytomegalovirus infection without neurologic symptoms at one year of age. Pediatrics 1997, 99:800-803.
5. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp 55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990, 64:1079-1085.
6. Bourne N., Schleiss M.R., Bravo F.J., Bernstein D.I. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. J Infect Dis 2001, 183:59-64.
7. Schleiss M.R., Bourne N., Stroup G., Bravo F.J., Jensen N.J., Bernstein D.I. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004, 189:1374-1381.
8. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
9. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001, 183:1171-1179.
10. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28:484-493.
11. Wloch M.K., Smith L.R., Boutsaboualoy S., Reyes L., Han C., Kehler J., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008, 197:1634-1642.
12. Kharfan-Dabaja M.A., Boeckh M., Wilck M.B., Langston A.A., Chu A.H., Wloch M.K., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.
13. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2007, 195:789-798.
14. + T-cell memory. Nat Med 2001, 7:913-919.
15. Pinschewer D.D., Perez M., Jeetendra E., Bachi T., Horvath E., Hengartner H., et al. Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest 2004, 114:988-993.
16. + T cell immunity. Nat Med 2010, 16:339-345.
17. Bratcher D.F., Bourne N., Bravo F.J., Schleiss M.R., Slaoui M., Myers M.G., et al. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 1995, 172:944-950.
18. Bia F.J., Griffith B.P., Fong C.K., Hsiung G.D. Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis 1983, 5:177-195.
19. Kumar M.L., Nankervis G.A. Experimental congenital infection with cytomegalovirus: a guinea pig model. J Infect Dis 1978, 138:650-654.
20. Harrison C.J., Britt W.J., Chapman N.M., Mullican J., Tracy S. Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis 1995, 172:1212-1220.
21. Bravo F.J., Cardin R.D., Bernstein D.I. Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2006, 193:591-597.
22. Bravo F.J., Bernstein D.I., Beadle J.R., Hostetler K.Y., Cardin R.D. Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Antimicrob Agents Chemother 2011, 55:35-41.
23. Schleiss M.R. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model. J Clin Virol 2008, 41:224-230.
24. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999, 180:970-975.
25. Adler S.P., Starr S.E., Plotkin S.A., Hempfling S.H., Buis J., Manning M.L., et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995, 171:26-32.
26. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
27. Lilja A.E., Mason P.W. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 2012, 30:6980-6990.
28. Schleiss M.R., Choi K.Y., Anderson J., Mash J.G., Wettendorff M., Mossman S., et al. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine 2014, 32:2756-2762.
29. Schleiss M.R., Bourne N., Bernstein D.I. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 2003, 188:1868-1874.
30. Swanson E.C., Gillis P., Hernandez-Alvarado N., Fernandez-Alarcon C., Schmit M., Zabeli J.C., et al. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality. Vaccine 2015, 33:4013-4018.
31. Hashimoto K., Yamada S., Katano H., Fukuchi S., Sato Y., Kato M., et al. Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta. Vaccine 2013, 31:3199-3205.
32. Pereira L., Petitt M., Fong A., Tsuge M., Tabata T., Fang-Hoover J., et al. Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. J Infect Dis 2014, 209:1573-1584.
33. Pereira L., Maidji E., McDonagh S., Tabata T. Insights into viral transmission at the uterine-placental interface. Trends Microbiol 2005, 13:164-174.
34. Pereira L., Petitt M., Tabata T. Cytomegalovirus infection and antibody protection of the developing placenta. Clin Infect Dis 2013, 57(Suppl 4):S174-S177.